Fundraising Fox
age1
Venture capitalSan Francisco · Pre-Seed–Series A · 10 people tracked
Find your way into age1
Each arrow is one introduction. Sign up to fill in the first one.
Ask Lloyd Johnston to introduce you to Alex Colville
You →Lloyd · together at Selecta Biosciences →Alex
Ask Jamie Chen to introduce you to Dr. Carolin Althoff
You →Jamie · together at Reframe Venture →Dr.
Ask Sam Okafor to introduce you to Laura Deming
You →Sam · together at Thiel Fellowship 2011 →Laura
- Satvik Dasariraju230 people can intro you
- Migon Choi57 people can intro you
- Lily Clayton1 person can intro you
Sign up to find every way you can get introduced to age1
- Your email: who you already know at age1, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the age1 team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
age1 backs contrarian founders developing therapeutics, tools, and technologies that target aging and age-related disease to extend healthy lifespan. The firm frames the shift from 'sickcare' to healthcare — preventing the onset of age-related disease rather than treating individual conditions — as a transformative moment in medicine. age1 invests at the earliest possible stage, often before any capital has been raised or even before a formal idea exists, and aims to build a pragmatic, rigorous, and optimistic longevity community. It prefers to lead rounds to secure founder-friendly terms and is capitalized to follow on in later rounds. It evolved from the Longevity Fund and a 2018 accelerator into a dedicated firm.
Source: firm website, verified Sep 26, 2026.
Team · 10 people
from the firm's website & curated
What they invest in
from 25 of 28 portfolio companiesBiotech ×24Healthtech ×12Deep Tech ×10Longevity ×9AI & Machine Learning ×7Medical Devices ×6Digital Health ×3AdTech ×1
HQs:United States×17
Who they back
founder profiles across 18 portfolio companiesFounding team size:solo founder×62 founders×83 founders×24+ founders×2
Where their founders studiedfrom 20 founders with education data
Duke University ×3Stanford University ×2The Johns Hopkins University School of Medicine ×2University of California, San Francisco ×2University of Oxford ×2
What their founders studiedfrom 20 founders with field-of-study data
Life Sciences ×14Engineering ×4Physics ×4Computer Science ×2
Where their founders worked beforefrom 20 founders with career history
IBM ×2Korro Bio ×2OpenAI ×2
15 founders hold a PhD (of 20 with degree data)
Investments · 28 tracked
founders shown can be your intro pathBy year:2026 · 32025 · 32020 · 12019 · 12018 · 12015 · 110 dated
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsLightstone VenturesForesite CapitalHBM Healthcare InvestmentsHBM PartnersvenBio PartnersLogos+1 more
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)inJennifer Doudna(Co-founder)Jose Rivera(Executive Officer)inJohn Leonard(President and Chief Executive Officer)inJames Basta(Executive Vice President, General Counsel and Corporate Secretary)inEdward Dulac(Executive Vice President, Chief Financial Officer)in
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalOrbiMedRidgeback Capital+2 more
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsAgent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+6 more
Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.
BiotechLongevitySan Francisco, US
Co-investorsValhalla VenturesKleiner PerkinsSoftBank Group
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Co-Founder)inJack O’Meara(Cofounder)in
Co-investorsBackedBlueYard CapitalEntrepreneur FirstGlobal Health Investment CorporationIaso VenturesLingotto+6 more
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)in
Co-investorsXEIA Venture Partners
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases.
AI & Machine LearningBiotechDigital HealthLongevityMedical DevicesAustin, US
Adam Freund(Founder & Chief Executive Officer)inRemi-Martin Laberge(Founder and Chief Technology Officer)in
BoardVineeta Agarwala(Director)in
Co-investorsAlumni VenturesAndreessen HorowitzGV (Google Ventures)LifelinkOlima VenturesRV Invest GmbH+7 more
Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.
BiotechDeep TechHealthtechBerkeley, US
Matt Krisiloff(CEO)inBianka Seres(President)in
Co-investorsCompoundHOF CapitalMetaplanetSciFoundersVU Venture Partners
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.
BiotechDigital HealthLongevitySan Francisco, US
Robin Mansukhani(CEO and Co-Founder)inAnil Bhushan(Scientific Founder)in
BoardDylan Morris(Director)in
Co-investorsBold Capital PartnersCornucopian Capital ManagementCRV (Charles River Ventures)Lifespan Vision VenturesOwl CapitalquadraScope Venture Fund+2 more
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsFarvatn VentureGRIDS CapitalLifeforce CapitalLifespan Vision VenturesMetaplanetPalo Santo VC+6 more
General Control is developing programmable, multiplexed epigenetic editing therapies designed to control the expression of several genes at once.
BiotechDeep TechLongevity
Lada Nuzhna(CEO & Founder)in
Co-investorsAngel Collective Opportunity FundGoAhead VenturesMoth FundStreamlined Ventures
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)in
Co-investorsY CombinatorFelicis VenturesFreemind InvestmentsLifespan Vision VenturesModi VenturesCoughdrop Capital+2 more
Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan.
AI & Machine LearningBiotechHealthtechLongevity
Co-investorsFifty YearsMetaplanetPrime Movers LabStreamlined VenturesW venturesW Ventures+1 more
A venture capital firm focused on the longevity sector, backing founder-driven companies working on extending human healthy lifespan.
BiotechLongevity
Laura Deming(Founder)inAlex Colville(General Partner)in
Co-investors1517Collaborative Fund
Loyal develops longevity drugs for dogs, targeting the biological processes of aging to extend healthy lifespan and reduce age-associated disease.
BiotechHealthtechLongevity
Celine Halioua(Founder & CEO)in
Co-investorsBain Capital VenturesBoxGroupCollaborative FundFirst Round CapitalFlucas VenturesInvariantes Fund+16 more
Loyal is a CTV and mobile publishing platform that owns and operates apps across iOS and Android while providing AI-powered ad technology through the Loyal Exchange to monetize inventory for publishers and partners.
AdTechConsumerMarketing TechMedia & EntertainmentSaaS
Tom Kenney(CEO)in
Co-investorsBlueRun VenturesTribeca Venture PartnersCrosscut VenturesBaillie Gifford
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsEcoR1 CapitalLAVLifeSci Venture PartnersLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+8 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Co-investorsBrace PharmaSanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Co-founder)inBlake Byers(Co-founder)inJacob Kimmel(Co-founder & CEO)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract VenturesBeyond CapitalCapital B Private Holdings+15 more
Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier.
BiotechHealthtechSan Francisco, US
Aaron Friedman(Executive Officer)Vladimir Senatorov(Director)
BoardTracy Saxton(Director)James Summers(Director)Brian Slingerland(Director)
Co-investorsDolby Family Ventures
Science Corporation develops brain-computer interface and neural engineering technology to restore vision, cognition, and mobility to patients with debilitating conditions.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesAlameda, US
Max Hodak(Chief Executive Officer)
Co-investors885 CapitalArtis VenturesAvalanche VCBeyond CapitalConversion CapitalDuke Capital Partners+14 more
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Co-investorsPillar VCKdT Ventures
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Nathaniel E. David(Executive Officer, Director)inDan Marquess(Executive Officer)inKeith Leonard(Executive Officer, Director)inTamara Tompkins(Executive Officer)inBob Goeltz(Executive Officer)inJamie Dananberg(Executive Officer)in
Co-investorsAlumni VenturesARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla VenturesVenrock+6 more
The company builds technology focused on improving patient outcomes in healthcare.
BiotechDeep TechMedical Devices
Co-investorsLux CapitalField VenturesFounders Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aperture TherapeuticsDecibel TherapeuticsMatinas / Metacrine
Exits · 6
4 IPOs · 2 acquisitions · showing 5Alx OncologyNASDAQ: ALXOIntellia TherapeuticsNASDAQ: NTLAPrecision BioSciencesNASDAQ: DTILDecibel Therapeuticsacq. by RegeneronDecibeltxacq. by Regeneron
Portfolio news
latest coverage across their companies
Loyal · finsmes.com · Feb 11, 2026
Skeletalis · finsmes.com · Nov 17, 2025
Frequently asked questions
- How many investments has age1 made?
- age1 has 28 tracked investments, 6 of which have exited, including 6 dated in the last 24 months.
- What stage does age1 invest at?
- age1 invests at the Pre-Seed, Seed, Series A stages.
- What is age1's typical check size?
- age1 typically writes checks of $500K – $4M.
- What sectors does age1 focus on?
- age1 focuses on AI & Machine Learning, Biotech, Healthtech, Longevity.
- Where is age1 located?
- age1 is headquartered in San Francisco, US.
- Does age1 lead rounds?
- Yes, age1 leads investment rounds.
- Who does age1 co-invest with?
- age1 most often shares deals with Metaplanet, EcoR1 Capital, Khosla Ventures, among 121 tracked co-investors.
Media · Podcasts & interviews
featuring the teamRoundtable with Alex Colville of AGE1: Revolutionizing Global Healthcare
Longevity Biotechnology Association · Alex Colville
Dr. Alex Colville, Ph.D., Co-Founder & General Partner - age1 - Longevity Biotech Venture Investing
Progress, Potential, and Possibilities · Alex Colville
Dr. Alex Colville, Ph.D. - Co-Founder and General Partner - age1
Progress, Potential, and Possibilities · Alex Colville
Age1’s Alex Colville: “Inventing the anti-ageing pill” - The Times Tech Podcast | Acast
Alex Colville · shows.acast.com
Images
Co-investors · 3
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Abstract is a San Francisco-based venture capital firm managing $1.8 billion in assets, investing in seed and early-stage companies across all sectors.
Refactor is a seed-stage venture firm run as a solo capitalist by Zal, backing founders building hard tech companies that address real-world problems.
Firms observed investing alongside age1, from public investor directories. Shared companies are the overlap with age1's recorded portfolio.
Similar investors
Boundary Capital invests in high-growth private technology companies with the aim of positively impacting millions of lives, focusing on life sciences, AI, and engineering.
Future Positive Capital is a venture firm backing entrepreneurs building companies that address large-scale global challenges across health, sustainability and technology.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
AlleyCorp is an early-stage investor and incubator based in New York that builds and backs companies across enterprise, consumer, healthcare, and deep tech sectors.
Medical Excellence Capital (MEC) is a venture firm focused on precision health and life sciences, pairing investment professionals and operators with a proprietary national medical network platform.